The current single-blind, randomized, controlled, clinical trial was conducted in an educational center (Firouzgar general hospital) in Tehran, Iran. Informed consent was obtained from all participants.
2.1. Inclusion Criteria
All the patients aged 18 to 65 years with ASA (American society of anesthesiology) physical status class I, scheduled for septorhinoplasty.
The current study was registered at www.IRCT.ir database under the code: IRCT201601129768N4.
Exclusion criteria were a history of nasal surgery, any allergic reactions to nitrates, and taking sildenafil or other similar drugs.
Patients were assigned into 2 groups by the simple randomization method (flipping a coin).
Both the patients and the surgeons were blind to grouping, but the anesthesiologist was aware of each patient group to be able to control any probable drug complications.
Sample size in each group was 30 patients; based on the previous studies conducted on controlled hypotension issue.
All of the patients received isotonic crystalloid (5 mL/kg) to replace compensatory intravascular expansion volume before starting anesthesia. Premedication and induction of anesthesia was similar in all patients: midazolam 0.03 mg/kg and fentanyl 3 mcg/kg for premedication, followed by propofol 2 mg/kg and atracurium 0.5 mg/kg to induce anesthesia. Mo maintain the anesthesia, propofol 100 mcg/kg/minute, atracurium 7 mcg/kg/minute, and fentanyl 50 mcg every 60 minutes were used. Head up position to 20 degrees was applied to all patients and all of the operations were performed by the same surgeon. After induction of anesthesia, patients were intubated and if they were hemodynamically stable, the surgeon allowed infiltrating local epinephrine to reduce bleeding tendency. Before starting surgical manipulation, if the mean arterial blood pressure was above 65 mmHg, infusion of TNG or labetalol according to the designed protocol was started to reach the target blood pressure (mean arterial blood pressure of 60 to 65 mmHg). The protocol was as follows:
In TNG group, the infusion started with 0.1 mcg/kg/minute and increased to the upper limit of 1 mcg/kg/minute if necessary. If during TNG infusion heart rate exceeded 100 beat/minute dosing was reduced to ameliorate this complication. The TNG used in the current study was a provided from Caspian Pharmaceutical Company in Iran, which contained 10 mg of the drug in 2 mL containing vials.
In the labetalol group, if heart rate exceeded 60 beat/minute patients first received a bolus dose of 0.25 mg/kg, and then, infusion of labetalol started with 2 mg/minute, which increased to 4 mg/minute if necessary. The current study limit in total amount of labetalol dosage was 300 mg. Any time during labetalol infusion, if heart rate dropped below 50 beat/minute, the infusion was held transiently and if heart rate dropped below 45 beat/minute, in spite of holding labetalol drip, then, 0.5 mg IV atropine was given. The used labetalol was a product of Kern Pharma SL Company in Spain containing 100 mg of the agent in 5 mL vials.
In each of the groups, if target blood pressure (controlled hypotension) was not achieved in any patient by the applied method, 0.5 MAC isoflurane was added to anesthetic drug regimens. Patients were monitored with noninvasive blood pressure (every 5 minutes), electrocardiography (ECG), and pulse-oximetry. Data were recorded every 15 minutes by an anesthetist who was ignorant of the type of administered hypotensive drug. On the other hand, the surgeon did not know anything about the drugs being used.
To minimize any complications related to tissue hypo-perfusion, the duration of controlled hypotension was considered less than 2 hours. Bleeding volume was measured by the amount of suctioned blood and the blood remaining in surgical gauzes at the end of surgery (surgical gauzes were assumed to contain 10 mL of blood). The quality of surgical field was assessed by surgeon’s satisfaction, based on a 5-option Likert scale rating system (very bad, bad, fair, good, very good).